In contrast, co-treatment with either PF-06409577 or the TAK1 inhibitor 5Z-O attenuated the increased cell migratory and invasive capacities caused by AMPKα1 knockdown in ovarian cancer cells (Fig. 6d). Here, MAP3K7 is linked to ovarian cancer.